Merck’s promising melanoma drug

Biopharmaceutical company Merck said an experimental
cancer drug showed promise in an early-stage trial of skin-cancer patients,
staking the company’s ground in an emerging race to develop medicines that
unleash the immune system’s power to fight malignancies. The drug, known as
MK-3475, is among a new class of agents called PD-1 inhibitors. Researchers
believe the medicines work by releasing a biological brake that shields tumor
cells from attack by the immune system. In interfering with the action of a
protein called PD-1, the drugs enable the immune system to home in on cancer
cells. This route is also attractive to Immunovo. Read more about the
developments within Immunovo on this site. Read here more about Merck’s new